SPONSOR

Memorial Sloan Kettering Cancer Center

Total Trials

Recruiting

Phases

Phase 1, Phase 1, Phase 2, Phase 2, EARLY_Phase 1, Phase 3

Conditions studied: Cutaneous T-cell Lymphoma Non-Small Cell Lung Cancer Educational Materials for Genetic Testing Breast Cancer Ovarian Cancer Prostate Cancer Pancreatic Cancer Colorectal Cancer Wilms Tumor Rhabdoid Tumor

Memorial Sloan Kettering Cancer Center (MSK) is the world's oldest and largest private cancer center, located in New York City with regional outpatient locations across the greater New York and New Jersey area. MSK is an NCI-designated comprehensive cancer center and a major sponsor and site for investigator-initiated cancer clinical trials, with a particular emphasis on Phase 1 first-in-human studies, novel immunotherapy strategies, and precision oncology. MSK's research enterprise integrates laboratory science and clinical investigation more tightly than almost any other institution, allowing laboratory discoveries to be rapidly translated into clinical trials.

MSK is home to specialized programs in virtually every cancer type, including the Evelyn H. Lauder Breast Center, the David H. Koch Center for Cancer Care, the Josie Robertson Surgery Center, and the Parker Institute for Cancer Immunotherapy — a multi-institution collaboration that has advanced CAR-T cell therapy, cancer vaccines, and immune checkpoint research. MSK's Department of Medicine, Human Oncology and Pathogenesis Program (HOPP), and the Computational Oncology Program develop and test novel therapeutic hypotheses across a pipeline of early-phase trials.

Pharmacogenomics and genomics-driven trial design are central to MSK's research model. The institution uses the MSK-IMPACT tumor sequencing panel — a 505-gene next-generation sequencing assay — on virtually all tumor biopsies from patients seen at MSK, enabling enrollment in genotype-matched basket trials and providing a rich biomarker-linked clinical database. MSK was a founding member of the AACR Project GENIE consortium, which aggregates genomic and clinical data from 19 major cancer centers worldwide.

Frequently Asked Questions — Memorial Sloan Kettering Cancer Center

What Phase 1 clinical trials does Memorial Sloan Kettering offer?

MSK's Phase 1 Drug Development Program is one of the largest and most established in the United States, evaluating approximately 50–80 first-in-human or early-phase trials at any given time. These trials test novel small molecules, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, CAR-T and NK cell therapies, and cancer vaccines. Most Phase 1 trials at MSK require patients to have exhausted standard treatment options and to have good performance status. Eligibility is typically evaluated by MSK's Phase 1 team after review of medical records; referrals from outside physicians are accepted and encouraged.

What is MSK-IMPACT and how does it affect trial eligibility?

MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) is a tumor sequencing assay that profiles 505 cancer-associated genes for mutations, copy number alterations, and structural rearrangements. Since 2014, MSK has performed MSK-IMPACT on tumor samples from nearly all patients treated at the center. The resulting genomic data is linked to clinical outcomes in the MSK cancer data platform (available via cBioPortal.org) and used to match patients to genomically-selected clinical trials — basket trials that enroll patients with a specific mutation regardless of tumor origin, such as BRAF, NTRK, RET, and HER2 alterations. Patients referred to MSK can often have their tumor sequenced as part of care.

Does MSK accept patients from outside New York for clinical trial enrollment?

Yes. MSK accepts referred patients from across the United States and internationally for clinical trial evaluation. Outpatient locations in New Jersey, Long Island, Westchester, and Connecticut expand access for regional patients. For patients traveling from farther away, MSK's Patient Access Service coordinates scheduling and provides recommendations for accommodations. Some trials — particularly immunotherapy infusion protocols — require patients to remain within a defined distance of MSK for safety monitoring during the initial treatment cycles. MSK social workers can help identify lodging assistance programs for patients in financial need.

Memorial Sloan Kettering Cancer Center

Frequently Asked Questions — Memorial Sloan Kettering Cancer Center

Clinical Trials by Memorial Sloan Kettering Cancer Center

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

A Study of Mental Health Care in People With Cancer

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy

A Study of a Weight Loss Intervention in People With Endometrial Cancer

A Study of CRD3874-SI in People With Solid Tumors

A Study of Sacituzumab Govitecan in People With Mesothelioma

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Genomic Profiling in Cancer Patients

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

Registry for Bone Metastases

Tislelizumab in People With Colorectal Cancer

A Study of Blood Pressure Control During Cancer Treatment

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

A Study of a Side Effects and Resource Navigation Program for People With Cancer

Retrospective Review of Esophageal Cancer at MSKCC

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma